Transcriptional and methylation outcomes of didehydro-cortistatin A use in HIV-1–infected CD4 + T cells
Life Science Alliance · 2024
DOI: 10.26508/lsa.202402653 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von Luisa P Mori und 7 weiteren Autor:innen. Beteiligte Einrichtung: The Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, FL, USA. Hauptthemen laut MEDLINE: HIV-1, CD4-Positive T-Lymphocytes, HIV Infections, DNA Methylation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIDA NIH HHS, Intramural NIH HHS.
Abstract (Originalsprache)
Ongoing viral transcription from the reservoir of HIV-1 infected long-lived memory CD4 + T cells presents a barrier to cure and associates with poorer health outcomes for people living with HIV, including chronic immune activation and inflammation. We previously reported that didehydro-cortistatin A (dCA), an HIV-1 Tat inhibitor, blocks HIV-1 transcription. Here, we examine the impact of dCA on host immune CD4 + T-cell transcriptional and epigenetic states. We performed a comprehensive analysis of genome-wide transcriptomic and DNA methylation profiles upon long-term dCA treatment of primary human memory CD4 + T cells. dCA prompted specific transcriptional and DNA methylation changes in cell cycle, histone, interferon-response, and T-cell lineage transcription factor genes, through inhibition of both HIV-1 and Mediator kinases. These alterations establish a tolerogenic Treg/Th2 phenotype, reducing viral gene expression and mitigating inflammation in primary CD4 + T cells during HIV-1 infection. In addition, dCA suppresses the expression of lineage-defining transcription factors for Th17 and Th1 cells, critical HIV-1 targets, and reservoirs. dCA’s benefits thus extend beyond viral transcription inhibition, modulating the immune cell landscape to limit HIV-1 acquisition and inflammatory environment linked to HIV infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, FL, USA.
- Department of Immunology and Microbiology, The Herbert Wertheim UF Scripps Institute for Biomedical Innovation & Technology, Jupiter, FL, USA.
- Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, NY, USA.
- The Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, FL, USA svalente@ufl.edu.
ORCID-Profile: Susana T Valente
Förderung
- NIAID NIH HHS
- NIDA NIH HHS
- Intramural NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases
Zitieren
APA
Mori, L. P., Corley, M. J., McAuley, A. T., Pang, A., Venables, T., Ndhlovu, L. C., Pipkin, M. E., & Valente, S. T. (2024). Transcriptional and methylation outcomes of didehydro-cortistatin A use in HIV-1–infected CD4 + T cells. Life Science Alliance. https://doi.org/10.26508/lsa.202402653
Vancouver
Mori LP, Corley MJ, McAuley AT, Pang A, Venables T, Ndhlovu LC, et al. Transcriptional and methylation outcomes of didehydro-cortistatin A use in HIV-1–infected CD4 + T cells. Life Science Alliance. 2024. doi:10.26508/lsa.202402653
BibTeX
@article{Mori2024,
author = {Mori, Luisa P and Corley, Michael J and McAuley, Andrew T and Pang, Alina and Venables, Thomas and Ndhlovu, Lishomwa C and Pipkin, Matthew E and Valente, Susana T},
title = {Transcriptional and methylation outcomes of didehydro-cortistatin A use in HIV-1–infected CD4 + T cells},
journal = {Life Science Alliance},
year = {2024},
doi = {10.26508/lsa.202402653}
}
EUVIMED